Comparison

Anti-Mouse Dendritic Cells - Purified - 50 µg

Item no. LEIN-D104-50ug
Manufacturer Leinco Technologies
Amount 50 ug
Quantity options 500 ug 50 ug
Category
Type Antibody Monoclonal
Applications FC, FA
Clone 33D1
Specific against Mouse (Murine, Mus musculus)
Host Rat
Citations Steinman, R. M. et al. (1982) Pro. Natl. Acad. Sci. USA 79:161
Steinman, R. M. et al. (1983) J. Exp. Med. 157:613
Nussenzweig et al. 1982. Proc Natl Acad Sci U S A. 79(1):161-5. PMID: 6948298.
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping Condition Room temperature
Available
Manufacturer - Category
Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers
Manufacturer - Targets
Dendritic Cells
Country of Origin
USA
Shipping Temperature
Next Day Ambient
Storage Conditions
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Product Description
Dendritic cells are antigen presenting cells that have two functions. They scan the body collecting and processing antigen material that they present on the cell surface to T cells, and they maintain T cell tolerance to “self”. The morphology of dendritic cells is characterized by an extremely large surface-to-volume ratio. Murine splenic dendritic cells can occur in two types: myeloid (cDC) and lymphoid (pDC). Lymphoid dendritic cells produce high amounts of IFN-α and are also called Plasmacytoid dendritic cell because they have an appearance similar to plasma cells. Myeloid, or conventional dendritic cells, secrete IL-12, IL-6, TNF, and chemokines and can be further categorized into three subtypes (CD4−CD8+, CD4+CD8− and CD4−CD8−). These differ from other migratory dendritic cells such as Langerhans cells and interstitial dendritic cells that migrate from peripheral tissues to the lymph nodes. The exact nature and biological activity of the dendritic cell surface marker DCIR2 is currently unknown. DCs are known to play a role in several diseases including myeloid cancer, pDC leukemia, HIV, lupus erythematosus, Crohn's disease and ulcerative colitis. However, it is thought that DCs may be able to control cancer progression because increased densities of DC populations have been linked with better clinical outcome. Lung cancers have been found to include four different subsets of dendritic cells; some of which can activate immune cells that can suppress tumor growth. Dendritic cells have also been shown to play a role in the success of cancer immunotherapies in experimental models. Specifically, the immune checkpoint blocker anti-PD-1 has been shown to indirectly activate DCs through IFN-γ released from drug-activated T cells. Agonizing the non-canonical NF-κB pathway also activates DCs and further enhances anti-PD-1 therapy in an IL-12-dependent manner.
Background
Dendritic cells are antigen presenting cells that have two functions. They scan the body collecting and processing antigen material that they present on the cell surface to T cells, and they maintain T cell tolerance to “self”. The morphology of dendritic cells is characterized by an extremely large surface-to-volume ratio. Murine splenic dendritic cells can occur in two types: myeloid (cDC) and lymphoid (pDC). Lymphoid dendritic cells produce high amounts of IFN-α and are also called Plasmacytoid dendritic cell because they have an appearance similar to plasma cells. Myeloid, or conventional dendritic cells, secrete IL-12, IL-6, TNF, and chemokines and can be further categorized into three subtypes (CD4−CD8+, CD4+CD8− and CD4−CD8−). These differ from other migratory dendritic cells such as Langerhans cells and interstitial dendritic cells that migrate from peripheral tissues to the lymph nodes. The exact nature and biological activity of the dendritic cell surface marker DCIR2 is currently unknown. DCs are known to play a role in several diseases including myeloid cancer, pDC leukemia, HIV, lupus erythematosus, Crohn's disease and ulcerative colitis. However, it is thought that DCs may be able to control cancer progression because increased densities of DC populations have been linked with better clinical outcome. Lung cancers have been found to include four different subsets of dendritic cells; some of which can activate immune cells that can suppress tumor growth. Dendritic cells have also been shown to play a role in the success of cancer immunotherapies in experimental models. Specifically, the immune checkpoint blocker anti-PD-1 has been shown to indirectly activate DCs through IFN-γ released from drug-activated T cells. Agonizing the non-canonical NF-κB pathway also activates DCs and further enhances anti-PD-1 therapy in an IL-12-dependent manner.
PubMed
Dendritic Cells
Manufacturer - Research Area
Immunology
Manufacturer - Specificity
Clone 33D1 recognizes mouse DCIR2.
RRID
AB_2829890
Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution
Murine DCIR2 is found on dendritic cells of the thymus, spleen, lymph nodes, and Peyer’s patches. DCs in the bone marrow may express DCIR2 in the presence of GM-CSF. However, this expression is notably downregulated when IL-4 is present. Furthermore, DCIR2 has been found In vivo on brain dendritic cells post infection with T. gondii.
Immunogen
Dendritic cells
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
Monoclonal Antibody, Dendritic Cells, 33D1, Mouse Dendritic Cells, Anti-Mouse Dendritic Cells Purified, Clone 33D1, Mouse Dendritic Cells Purified

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 ug
Available: In stock
available

Delivery expected until 10/30/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close